Skip to main content
. 2013 Mar;98(3):428–432. doi: 10.3324/haematol.2011.056135

Figure 1.

Figure 1.

Treatment outcome of patients with pediatric ALL comparing patients with and without IKZF1 deletions. Kaplan-Meier estimates for the whole cohort of 694 patients: (A) event-free survival (EFS) at 5 years, (B) cumulative incidence of relapse (CIR) at 5 years, and (C) overall survival (OS) at 5 years. For the intermediate risk group: (D) EFS, (E) CIR, and (F) OS.